What is the 13F Pro Quality Score for BIIB?

13F Pro ranks BIOGEN INC. (BIIB) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BIIB's current score at https://13fpro.ai/company/BIIB (free sign-up required for the full ranking).

Which hedge funds own the most BIIB stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of BIIB include FMR, BlackRock,, PRIMECAP MANAGEMENT CO/CA/. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/BIIB as soon as new 13F filings post.

Where does 13F Pro source BIIB data?

All BIOGEN INC. fundamentals and ownership data come directly from SEC EDGAR. BIOGEN INC. files with the SEC under CIK 875045. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BIIB in?

BIOGEN INC. (BIIB) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives BIIB's revenue?

Per BIOGEN INC.'s latest 10-Q filed with the SEC on 2026-07-29, the biggest revenue drivers are: Product revenue, net ($1,916.4M, +2.0% YoY); Revenue from anti-CD20 therapeutic programs ($513.5M, +9.9% YoY); Multiple Sclerosis ($963.3M, -13.0% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/BIIB.

How often is BIIB research updated on 13F Pro?

BIIB's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BIOGEN INC.(BIIB)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqlarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 875045 BIIB stock profile & AI dashboard →

13F Pro Quality Score

64.7/100

Rank #526 of 2,961 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

28.7/100

Profitability

68.9/100

Balance Sheet

69.0/100

Earnings Quality

81.8/100

Free Cash Flow

78.2/100

Institutional Flow

85.9/100

Revenue Scale

86.5/100

Dilution Risk

33.1/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why BIIB Scores 65/100

exact factor attribution · 2026-09-10

BIIB's composite is driven by scale and free cash flow, held back by revenue growth. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Scale

+5.5 pts

87th pct

Free cash flow

+4.2 pts

78th pct

Earnings quality

+3.2 pts

82th pct

Profitability

+2.8 pts

69th pct

Capital efficiency

+1.9 pts

69th pct

Institutional flow

+1.8 pts

86th pct

Earnings growth

+0.4 pts

57th pct

Shareholder dilution

-0.8 pts

33th pct

Revenue growth

-4.2 pts

29th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

BIIB Stock Analysis & AI Quality Score

Data updated 2026-09-10

AI stock analysis and institutional research for BIOGEN INC. (BIIB), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BIIB at 64.7/100 on a 32-signal composite quality model, placing it at rank #526 of 2,961 stocks — the top 25% of the AI-ranked universe. BIIB scores in the top quartile across revenue scale (86.5), institutional flow (85.9), earnings quality (81.8). Areas of concern include revenue growth (28.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 33.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), BIOGEN INC. reports quarterly revenue of $2.5B, net income of $319.5M, an operating margin of 15.2%. Top institutional holders of BIIB by reported 13-F value include FMR, BlackRock, PRIMECAP MANAGEMENT, based on the most recent SEC filings. BIIB trades on the Nasdaq exchange and files with the SEC under CIK 875045. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BIIB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BIOGEN INC. directly from SEC EDGAR. BIOGEN INC.'s 13F Pro composite quality score has ranged between 54 and 75 since 2021, currently 64.7 — a declining long-term trajectory across 67 quarterly and live scoring snapshots.

✦

Fun facts about BIOGEN INC.

Quirks, history, and lore behind BIIB — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biotechnology company · large-cap · listed on Nasdaq · headquartered in Cambridge, Massachusetts.
2
The Numbers
Annual revenue in the range of $9–10 billion, yet sales have been under pressure for years as its flagship drugs face generic competition and pipeline bets run expensive.
3
The History
Founded in 1978 by a group that included a Nobel laureate, it was one of the earliest biotech companies ever created — practically a founding myth of the entire industry.
4
The Secret
Its core franchise is built around treating multiple sclerosis, and it has spent decades as the undisputed leader in a disease most pharma giants once ignored.
5
The Lore
It sparked one of biotech's wildest stock rollercoasters when the FDA granted accelerated approval to its controversial Alzheimer's drug in 2021 — dividing scientists and investors alike.
6
The Giveaway
The maker of Tecfidera and Tysabri for MS, and the company whose Alzheimer's bet on aducanumab made headlines around the world — for better and worse.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving BIIB's Business? Latest 10-Q Breakdown

✓ 32/32 datapoints verified

AI-extracted from BIOGEN INC.'s 10-Q filed 2026-07-29 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Revenue rose 3.4% to $2.74B, but net income fell 85% to $97.5M as Apellis acquisition costs — inventory step-up amortization, $165M restructuring, and a 26.4% tax rate — overwhelmed underlying growth.

Biggest Revenue Drivers

Product revenue, net$1,916.4M+2.0% YoY

MS decline offset by rare disease launch growth and newly acquired specialized immunology products

Revenue from anti-CD20 therapeutic programs$513.5M+9.9% YoY

Driven by OCREVUS royalty sales growth in the U.S.

Biggest Revenue Drivers

Total revenue: $2,736.0M+3.4% YoY

Product revenue, net$1,916.4M+2.0% YoY

MS decline offset by rare disease launch growth and newly acquired specialized immunology products

Within Product revenue, net

Multiple Sclerosis$963.3M-13.0% YoY

TECFIDERA down 53% on generic entrants; Interferon declining as patients shift to oral/higher-efficacy therapies

Rare Disease$601.7M+10.8% YoY

SKYCLARYS and QALSODY launch growth plus demand for high-dose SPINRAZA regimen

Specialized Immunology$127.8M

SYFOVRE and EMPAVELI revenue recognized since the May 14, 2026 Apellis acquisition closed

Revenue from anti-CD20 therapeutic programs$513.5M+9.9% YoY

Driven by OCREVUS royalty sales growth in the U.S.

Largest Expense Items

Cost of sales (excl. amortization/impairment)$776.9M+28.4% YoY

Higher amortization from acquired inventory fair-value step-up (SKYCLARYS, SYFOVRE, EMPAVELI) and higher revenue

Selling, general and administrative$709.7M+21.6% YoY

Inclusion of Apellis commercial operations plus increased sales and marketing spend on product launches

Research and development$529.6M+32.7% YoY

SKYCLARYS inventory step-up amortization, higher clinical trial spend (felzartamab, salanersen, litifilimab), Apellis opex

Acquired IPR&D, upfront and milestone expense$164.0M+251.9% YoY

Driven by $100.0M upfront payment to TJ Bio and Ionis milestone/option payments

Margins: Cost of sales, R&D and SG&A all grew faster than revenue due to Apellis acquisition-related inventory step-up amortization and integration costs, while restructuring charges and a spike in the effective tax rate to 26.4% (from non-deductible acquisition expenses) drove net income down sharply despite revenue growth.

Watch Items from the Filing

Diluted EPS fell 84.8% YoY to $0.66 from $4.33 despite revenue growth, driven by Apellis acquisition costs, restructuring charges, and a higher tax rate.
Global TECFIDERA revenue fell 53.0% YoY to $90.9M after EU patent revocation opened the door to generic entrants; further declines expected.
Three wholesalers accounted for 29.9%, 16.5%, and 10.9% of gross product revenue in Q2 2026, indicating customer concentration.
The $5.3B Apellis acquisition was funded partly by a $2.0B term loan and $400M revolver draw, pushing total borrowings to $8.1B and adding $800M of current debt.
A new 100% Section 232 tariff on patented pharmaceuticals/biologics takes effect July-September 2026; company does not expect a material 2026 impact but flags substantial uncertainty.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$2.5B

Net Income

Q1 2026

$319.5M

Free Cash Flow

Q1 2026

$594.3M

Operating Margin

Q1 2026

15.2%

ROIC

Q1 2026

6.1%

D/E Ratio

Q1 2026

0.34

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+2.2% YoY

$9.89BFY 2025

FY22 $10.17BFY23 $9.84BFY24 $9.68BFY25 $9.89B

Net Income

-20.8% YoY

$1.29BFY 2025

FY22 $3.05BFY23 $1.16BFY24 $1.63BFY25 $1.29B

Operating Income

—FY 2025

FY22 —FY23 —FY24 —FY25 —

EPS (Diluted)

-21.4% YoY

$8.79FY 2025

FY22 $20.87FY23 $7.97FY24 $11.18FY25 $8.79

Total Assets

+5.0% YoY

$29.44BFY 2025

FY22 $24.55BFY23 $26.84BFY24 $28.05BFY25 $29.44B

Total Debt

-0.1% YoY

$6.29BFY 2025

FY22 $6.28BFY23 $6.94BFY24 $6.30BFY25 $6.29B

Op. Cash Flow

-23.3% YoY

$2.20BFY 2025

FY22 $1.38BFY23 $1.55BFY24 $2.88BFY25 $2.20B

Free Cash Flow

-24.7% YoY

$2.05BFY 2025

FY22 $1.14BFY23 $1.27BFY24 $2.72BFY25 $2.05B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$9.89B +2.2%	$9.68B -1.6%	$9.84B -3.3%	$10.17B -7.4%	$10.98B -18.3%	$13.44B
Net Income	$1.29B -20.8%	$1.63B +40.6%	$1.16B -61.9%	$3.05B +95.8%	$1.56B -61.1%	$4.00B
Operating Income	—	—	—	—	$2.84B -37.6%	$4.55B
EPS (Diluted)	$8.79 -21.4%	$11.18 +40.3%	$7.97 -61.8%	$20.87 +100.7%	$10.40 -58.1%	$24.80
Total Assets	$29.44B +5.0%	$28.05B +4.5%	$26.84B +9.3%	$24.55B +2.8%	$23.88B -3.0%	$24.62B
Total Debt	$6.29B -0.1%	$6.30B -9.3%	$6.94B +10.5%	$6.28B -13.6%	$7.27B -2.1%	$7.43B
Operating Cash Flow	$2.20B -23.3%	$2.88B +85.9%	$1.55B +11.8%	$1.38B -62.0%	$3.64B -13.9%	$4.23B
Free Cash Flow	$2.05B -24.7%	$2.72B +114.3%	$1.27B +11.0%	$1.14B -66.2%	$3.38B -11.1%	$3.81B

Get alerted when BIIB's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BIOGEN INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BIIB

FMR LLC
$3.9B18,217,239 sh
BlackRock, Inc.
$3.5B15,985,736 sh
PRIMECAP MANAGEMENT CO/CA/
$3.3B15,154,606 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.1B9,651,117 sh
STATE STREET CORP
$1.6B7,344,327 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$1.4B6,604,936 sh
GEODE CAPITAL MANAGEMENT, LLC
$957.9M4,449,295 sh
WELLINGTON MANAGEMENT GROUP LLP
$673.6M3,117,469 sh
NORGES BANK
$557.4M2,580,033 sh
MORGAN STANLEY
$521.0M2,411,271 sh

Fund	Value	Shares
FMR LLC	$3.9B	18,217,239
BlackRock, Inc.	$3.5B	15,985,736
PRIMECAP MANAGEMENT CO/CA/	$3.3B	15,154,606
VANGUARD CAPITAL MANAGEMENT LLC	$2.1B	9,651,117
STATE STREET CORP	$1.6B	7,344,327
VANGUARD PORTFOLIO MANAGEMENT LLC	$1.4B	6,604,936
GEODE CAPITAL MANAGEMENT, LLC	$957.9M	4,449,295
WELLINGTON MANAGEMENT GROUP LLP	$673.6M	3,117,469
NORGES BANK	$557.4M	2,580,033
MORGAN STANLEY	$521.0M	2,411,271

Companies Similar to BIIB

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

REGN

REGENERON PHARMACEUTICALS, INC.

AI score

Very similar · 32 shared holders

Robeco Institutional Asset Management B.V.CAISSE DE DEPOT ET PLACEMENT DU QUEBEC LSV ASSET MANAGEMENT

BMY

BRISTOL MYERS SQUIBB CO

AI score

Very similar · 38 shared holders

PRIMECAP MANAGEMENT CO/CA/Robeco Institutional Asset Management B.V.Employees Provident Fund Board

VRTX

VERTEX PHARMACEUTICALS INC / MA

AI score

Very similar · 39 shared holders

Robeco Institutional Asset Management B.V.National Pension Service Candriam S.C.A.

IQV

IQVIA HOLDINGS INC.

AI score

Very similar · 25 shared holders

Boston Partners National Pension Service Robeco Institutional Asset Management B.V.

MDT

Medtronic plc

AI score

Very similar · 24 shared holders

Boston Partners National Pension Service Swedbank AB

ZBH

ZIMMER BIOMET HOLDINGS, INC.

AI score

Very similar · 32 shared holders

PRIMECAP MANAGEMENT CO/CA/Boston Partners CAUSEWAY CAPITAL MANAGEMENT LLC

ABT

ABBOTT LABORATORIES

AI score

Very similar · 27 shared holders

Alyeska Investment Group, L.P.National Pension Service CAISSE DE DEPOT ET PLACEMENT DU QUEBEC

BSX

BOSTON SCIENTIFIC CORP

AI score

Very similar · 32 shared holders

PRIMECAP MANAGEMENT CO/CA/Employees Provident Fund Board CAISSE DE DEPOT ET PLACEMENT DU QUEBEC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BIIB on your watchlist

Track score changes the day BIOGEN INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BIIB a good stock to buy?

13F Pro's AI-powered analysis of BIOGEN INC. (BIIB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BIIB are available on the BIIB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BIIB is classified as a large company.

Which hedge funds own BIIB?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BIIB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BIOGEN INC.'s investment landscape.